Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ShareHope Medicine CoROCO:8403 72 EV-to-EBITDA is 6.51 as of Sep. 01, 2026, which is 28% below its 10-year median of 8.98. GuruFocus rates ROCO:8403 with a GF Score™ of 72/100 and a GF Value™ of NT$28.96 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 98 Medical Distribution companies, ShareHope Medicine Co ranks better than 62.24% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ShareHope Medicine Co's enterprise value is NT$3,264 Mil.
ShareHope Medicine Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$501 Mil. Therefore, ShareHope Medicine Co's EV-to-EBITDA for today is 6.51.
The historical rank and industry rank for ShareHope Medicine Co's EV-to-EBITDA or its related term are showing as below:
ROCO:8403'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.13 Med: 8.98 Max: 16.4
Current: 6.51
During the past 13 years, the highest EV-to-EBITDA of ShareHope Medicine Co was 16.40. The lowest was 4.13. And the median was 8.98.
ROCO:8403's EV-to-EBITDA is ranked better than 62.24% of 98
companies
in the Medical Distribution industry
Industry Median: 8.545
vs ROCO:8403: 6.51
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
ShareHope Medicine Co (ROCO:8403) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ShareHope Medicine Co's PE Ratio (TTM) for today is calculated as:
ShareHope Medicine Co's share price for today is NT$19.10.
ShareHope Medicine Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.190.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
ShareHope Medicine Co EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for ShareHope Medicine Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:8403 vs MCK, COR, CAH: EV-to-EBITDA Comparison
For the Medical Distribution subindustry, ShareHope Medicine Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ShareHope Medicine Co EV-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, ShareHope Medicine Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ShareHope Medicine Co's EV-to-EBITDA falls into.
ShareHope Medicine Co's current Enterprise Value is NT$3,264 Mil.
ShareHope Medicine Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$501 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ShareHope Medicine Co (ROCO:8403) has a EV-to-EBITDA of 6.51 as of Sep. 01, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ShareHope Medicine Co. This is 28% below median its historical median of 8.98. Over the past decade, ShareHope Medicine Co's EV-to-EBITDA has ranged from 4.13 to 16.40. According to the industry distribution chart, ShareHope Medicine Co ranks #37 out of 98 companies in the Medical Distribution industry, placing it in the top 37.8%.
Is ShareHope Medicine Co's EV-to-EBITDA too high?
ShareHope Medicine Co's current EV-to-EBITDA of 6.51 is 28% below median its 10-year median of 8.98. Over the past 10 years, this metric has ranged from a low of 4.13 to a high of 16.40. The Medical Distribution industry median EV-to-EBITDA is 8.55. ShareHope Medicine Co's value of 6.51 is 23.8% below this industry median. Based on the distribution chart, ShareHope Medicine Co ranks #37 out of 98 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, ShareHope Medicine Co has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ShareHope Medicine Co's EV-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, ShareHope Medicine Co ranks #37 out of 98 companies for EV-to-EBITDA. This puts ShareHope Medicine Co in the upper half of its industry. The industry median EV-to-EBITDA is 8.55. ShareHope Medicine Co's value of 6.51 is 23.8% below this benchmark. Historically, ShareHope Medicine Co's own EV-to-EBITDA has ranged from 4.13 to 16.40 over the past decade. While the company's 10-year median is 8.98 vs. the industry median of 8.55, ShareHope Medicine Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Distribution company?
The median EV-to-EBITDA among Medical Distribution companies is 8.55, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ShareHope Medicine Co's current EV-to-EBITDA of 6.51 is 23.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ShareHope Medicine Co. For the Medical Distribution industry, the median EV-to-EBITDA is 8.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ShareHope Medicine Co's current EV-to-EBITDA is 6.51, which is 28% below median its own 10-year median of 8.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ShareHope Medicine Co stock overvalued right now?
Based on GuruFocus' analysis, ShareHope Medicine Co (ROCO:8403) is currently considered Possible Value Trap. The stock's GF Value™ is NT$28.96, compared to a current price of NT$19.10 — trading 34% below its estimated fair value. The current EV-to-EBITDA is 6.51, which is 28% below median its 10-year median of 8.98 and 23.8% below the Medical Distribution industry median of 8.55. ShareHope Medicine Co's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For ShareHope Medicine Co (ROCO:8403), the current EV-to-EBITDA is 6.51 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ShareHope Medicine Co (ROCO:8403) Overvalued in 2026?
Based on GuruFocus' analysis, ShareHope Medicine Co stock appears to be undervalued.
The current stock price of NT$19.10 is trading 34% below its estimated GF Value™ of NT$28.96.
GuruFocus considers ShareHope Medicine Co to be Possible Value Trap.
Key valuation signals for ROCO:8403:
EV-to-EBITDA: 6.51 (28% below median its 10-year median of 8.98)
GF Value™: NT$28.96 vs. price of NT$19.10 (34% below fair value)
Industry Position: 23.8% below the Medical Distribution median (#37 of 98)
No single metric tells the full story. See the ROCO:8403 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ShareHope Medicine Co Ltd is engaged in wholesale and retail sales of medicines and hygiene materials, leasing of assets for medical institutions to undertake related medical services, and physical examinations for Taiwanese people and foreign labors, on-site medical support services, hemodialysis business management, ophthalmic medical management, clothing-related management services, manufacturing, processing and sales of various non-woven fabrics and management consulting for chain pharmacies in collaboration with medical institutions.
72GF Score
Get the complete analysis for ROCO:8403
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8403 has been successfully added to your 
